Babak B Navi1, Samuel Singer2, Alexander E Merkler2, Natalie T Cheng2, Jacqueline B Stone2, Hooman Kamel2, Costantino Iadecola2, Mitchell S V Elkind2, Lisa M DeAngelis2. 1. From the Department of Neurology (B.B.N., A.E.M., N.T.C., H.K., C.I., L.M.D.) and Feil Family Brain and Mind Research Institute (B.B.N., H.K., C.I.), Weill Cornell Medical College, New York, NY; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY (B.B.N., S.S., J.B.S., L.M.D.); and Department of Neurology, College of Physicians and Surgeons and the Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY (M.S.V.E.). ban9003@med.cornell.edu. 2. From the Department of Neurology (B.B.N., A.E.M., N.T.C., H.K., C.I., L.M.D.) and Feil Family Brain and Mind Research Institute (B.B.N., H.K., C.I.), Weill Cornell Medical College, New York, NY; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY (B.B.N., S.S., J.B.S., L.M.D.); and Department of Neurology, College of Physicians and Surgeons and the Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY (M.S.V.E.).
Abstract
BACKGROUND AND PURPOSE: Cryptogenic stroke is common in patients with cancer. Autopsy studies suggest that many of these cases may be because of marantic endocarditis, which is closely linked to cancer activity. We, therefore, hypothesized that among patients with cancer and ischemic stroke, those with cryptogenic stroke would have shorter survival. METHODS: We retrospectively analyzed all adult patients with active systemic cancer diagnosed with acute ischemic stroke at a tertiary care cancer center from 2005 through 2009. Two neurologists determined stroke mechanisms by consensus. Patients were diagnosed with cryptogenic stroke if no specific mechanism could be determined. The diagnosis of marantic endocarditis was restricted to patients with cardiac vegetations on echocardiography or autopsy and negative blood cultures. Patients were followed until July 31, 2012, for the primary outcome of death. Kaplan-Meier statistics and the log-rank test were used to compare survival between patients with cryptogenic stroke and patients with known stroke mechanisms. Multivariate Cox proportional hazard analysis evaluated the association between cryptogenic stroke and death after adjusting for potential confounders. RESULTS: Among 263 patients with cancer and ischemic stroke, 133 (51%) were cryptogenic. Median survival in patients with cryptogenic stroke was 55 days (interquartile range, 21-240) versus 147 days (interquartile range, 33-735) in patients with known stroke mechanisms (P<0.01). Cryptogenic stroke was independently associated with death (hazard ratio, 1.64; 95% confidence interval, 1.25-2.14) after adjusting for age, systemic metastases, adenocarcinoma histology, and functional status. CONCLUSIONS: Cryptogenic stroke is independently associated with reduced survival in patients with active cancer and ischemic stroke.
BACKGROUND AND PURPOSE: Cryptogenic stroke is common in patients with cancer. Autopsy studies suggest that many of these cases may be because of marantic endocarditis, which is closely linked to cancer activity. We, therefore, hypothesized that among patients with cancer and ischemic stroke, those with cryptogenic stroke would have shorter survival. METHODS: We retrospectively analyzed all adult patients with active systemic cancer diagnosed with acute ischemic stroke at a tertiary care cancer center from 2005 through 2009. Two neurologists determined stroke mechanisms by consensus. Patients were diagnosed with cryptogenic stroke if no specific mechanism could be determined. The diagnosis of marantic endocarditis was restricted to patients with cardiac vegetations on echocardiography or autopsy and negative blood cultures. Patients were followed until July 31, 2012, for the primary outcome of death. Kaplan-Meier statistics and the log-rank test were used to compare survival between patients with cryptogenic stroke and patients with known stroke mechanisms. Multivariate Cox proportional hazard analysis evaluated the association between cryptogenic stroke and death after adjusting for potential confounders. RESULTS: Among 263 patients with cancer and ischemic stroke, 133 (51%) were cryptogenic. Median survival in patients with cryptogenic stroke was 55 days (interquartile range, 21-240) versus 147 days (interquartile range, 33-735) in patients with known stroke mechanisms (P<0.01). Cryptogenic stroke was independently associated with death (hazard ratio, 1.64; 95% confidence interval, 1.25-2.14) after adjusting for age, systemic metastases, adenocarcinoma histology, and functional status. CONCLUSIONS: Cryptogenic stroke is independently associated with reduced survival in patients with active cancer and ischemic stroke.
Authors: Jin Myoung Seok; Seon Gyeong Kim; Ji Won Kim; Chin-Sang Chung; Gyeong-Moon Kim; Kwang Ho Lee; Oh Young Bang Journal: Ann Neurol Date: 2010-08 Impact factor: 10.422
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Lancet Date: 2007-10-20 Impact factor: 79.321
Authors: Darren R Feldman; Sujata Patil; Michael J Trinos; Maryann Carousso; Michelle S Ginsberg; Joel Sheinfeld; Dean F Bajorin; George J Bosl; Robert J Motzer Journal: Cancer Date: 2011-07-26 Impact factor: 6.860
Authors: Seon Gyeong Kim; Ji Man Hong; Hahn Young Kim; Jun Lee; Pil-Wook Chung; Kwang-Yeol Park; Gyeong-Moon Kim; Kwang Ho Lee; Chin-Sang Chung; Oh Young Bang Journal: Stroke Date: 2010-02-11 Impact factor: 7.914
Authors: Alexander E Merkler; Babak B Navi; Samuel Singer; Natalie T Cheng; Jacqueline B Stone; Hooman Kamel; Costantino Iadecola; Mitchell S V Elkind; Lisa M DeAngelis Journal: J Neurooncol Date: 2015-04-08 Impact factor: 4.130
Authors: Andrew D Schweitzer; Neal S Parikh; Gulce Askin; Ajay Nemade; John Lyo; Sasan Karimi; Anna Knobel; Babak B Navi; Robert J Young; Ajay Gupta Journal: Neuroradiology Date: 2017-03-13 Impact factor: 2.804
Authors: Yong-Won Shin; Soon-Tae Lee; Keun-Hwa Jung; Do-Yong Kim; Chul-Kee Park; Tae Min Kim; Seung Hong Choi; Kon Chu; Sang Kun Lee Journal: J Neurooncol Date: 2016-03-11 Impact factor: 4.130
Authors: Neal S Parikh; Jaclyn E Burch; Hooman Kamel; Lisa M DeAngelis; Babak B Navi Journal: J Stroke Cerebrovasc Dis Date: 2017-06-21 Impact factor: 2.136
Authors: Santosh B Murthy; Mary Cushman; Dylan Bobrow; Hooman Kamel; Alexander E Merkler; Mitchell S V Elkind; Lisa M DeAngelis; Babak B Navi Journal: J Clin Neurosci Date: 2018-08-23 Impact factor: 1.961
Authors: Markus Kneihsl; Christian Enzinger; Gerit Wünsch; Michael Khalil; Valeriu Culea; Tadeja Urbanic-Purkart; Franz Payer; Kurt Niederkorn; Franz Fazekas; Thomas Gattringer Journal: J Neurol Date: 2015-11-03 Impact factor: 4.849
Authors: Babak B Navi; Scott E Kasner; Mitchell S V Elkind; Mary Cushman; Oh Young Bang; Lisa M DeAngelis Journal: Stroke Date: 2021-01-28 Impact factor: 7.914